Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–45
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Overtly healthy females as determined by medical history, physical examination, and other screening procedures
Have a body mass index (BMI) equal to or above 18.5 kilograms per meter squared (kg/m²), at screening
Are not intending to start a family within 2 months after the study
You may not be if
Have known allergies to either tirzepatide or ethinylestradiol or norgestimate or related compounds
Have a medical condition or medical history that precludes the taking of combined oral contraceptives
Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase or gastrointestinal (GI) disorder (eg, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (eg, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors
Have used hormonal implants or received hormonal injections in the past 12 months
Unwilling to comply with smoking restrictions during the study
